Matinas BioPharma Cleared for Phase 1 Clinical Study of MAT2501 for the Treatment of Non-Tuberculous Mycobacterium Infections by FDA

Matinas BioPharma Holdings, Inc.(OTCQB:MTNB) announced that its Investigational New Drug (“IND”) application to the US Food and Drug Administration (“FDA”) is now open. The company is authorized to initiate a Phase 1 clinical study for investigational drug, MAT2501 (encochleated amikacin), for the treatment of  non-tuberculous mycobacterium (NTM) infections, its lead chronic indication.
Roelof Rongen, President and Chief Executive Officer of Matinas BioPharma, commented:

The encouraging preclinical data demonstrating MAT2501’s oral bioavailability and its targeted delivery of amikacin directly to the site of infection in NTM infections, gives us confidence as we prepare for our upcoming Phase 1 study.  Importantly, we believe our oral encochleated formulation of MAT2501 has the potential to address the many shortcomings that currently exist in the treatment of both chronic and acute bacterial infections with IV administration of amikacin, including major side effects associated with toxicity.

Click here to view the full press release.